Moderna (MRNA) Dropped, So What Is Behind The Latest Attention?
Moderna (MRNA) is back in focus after a busy stretch, with FDA approval of its mFlusiva flu shot and a pair of convertible note offerings that together total $4.6b in new financing.
For investors watching the tape, Moderna’s share price has surged over the past year, with a very large 1-year total shareholder return of 494.81%. However, the 1-day and 7-day share price returns are down 2.23% and 5.65%, hinting that the recent mFlusiva approval and fresh convertible note issuance are now being weighed against higher expectations and a reassessment of risk around the next phase of its mRNA pipeline.
Scan beyond Moderna and see how other healthcare names with resilient balance sheets and fundamentals are setting up right now through our curated list of solid balance sheet and fundamentals (24 results).
Moderna’s sharp rise over the past year, followed by this recent pullback, raises a simple question: Are investors now paying for mRNA progress, or mostly for shifting sentiment around the story?
Most Popular Narrative: 229% Overvalued
Moderna last closed at $145.55 compared with a widely followed fair value narrative of $44.25 per share, which frames the recent rally as rich against its modeled cash flows.
The analysts have a consensus price target of $44.25 for Moderna based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $77.0, and the most bearish reporting a price target of just $22.0.
Want to understand why this narrative still lands on a much lower value than Moderna's latest share price? The key is how fast revenue ramps, how margins are modeled to shift from deep losses, and which future earnings multiple is used on those projected profits. The full story is in how those three levers interact over the next few years, not just in a single target number.
Result: Fair Value of $44.25 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, that storyline leans heavily on smooth regulatory follow through and assumes competitive flu and RSV products do not curb Moderna’s pricing power or vaccine uptake.
Find out about the key risks to this Moderna narrative.
Next Steps
Feel like the Moderna story is pulling you in two directions at once? Take a closer look at both sides of the ledger and weigh the 1 key reward and 1 important warning sign.
Looking for more investment ideas beyond Moderna?
You do not have to stop with Moderna. Use clear stock screens to spot fresh opportunities, compare quality, and build a watchlist that actually reflects your plan.
- Target potential bargains by scanning for companies that combine resilient cash flows with supportive valuations through the 49 high quality undervalued stocks.
- Prioritise staying power by tracking businesses with stronger financial footing and robust fundamentals via the list of solid balance sheet and fundamentals (24 results).
- Hunt for potential future leaders that are not yet widely followed by using the 17 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com